The Contribution of Cell Blocks in the Diagnosis of Mediastinal Masses and Hilar Adenopathy Samples From Echobronchoscopy

The role of cytology in endobronchial ultrasound‐guided transbronchial needle aspiration: A study of 813 cases focusing on diagnostic yield, an analysis of misdiagnosed cases and diagnostic accordance rate of cytological subtyping

“…For the 805 EBUS‐TBNA specimens with cytology and histology, the implementation ratio of ICC and IHC was 1:6 (21‐125). In recent years, with the continuous improvement of cell block technology, it is completely feasible to implement IHC on cell blocks 22,23 . It is believed that with continued clinical application, the role of cell blocks in subtyping can be further improved and that the diagnostic accordance rate of cytological subtyping will be further improved.…”

EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part IV – EUS-guided Interventions: General aspects and EUS-guided sampling (Long Version)

“…In a number of clinical settings and target lesions, it is tissue architecture, immunohistochemistry and molecular analysis rather than cellular features that are essential for accurate pathological assessment [636,637]. For benign diseases, e. g. autoimmune pancreatitis [209,216], differential diagnosis of SET (GIST vs. leiomyoma or schwannoma) [94,280,288,290,295,298], subtyping of NSCLC and malignant lymphoma [310,332,361,424,538], diagnosis of rare tumors [221,340,521], grading of neuroendocrine tumors [203 -205], molecular profiling of solid tumors [180 -184, 186, 307 -309, 311 -313, 517, 643, 644] and differential diagnosis of mediastinal lymph node metastases [94,340,356], a core sample is preferred to a cytological aspirate [110]. Immunohistochemistry and molecular analysis will become increasingly important to allow personalized oncological treatment [180 -184, 186, 307 -309, 311 -313, 517, 643].…”

Untitled

“…In a number of clinical settings and target lesions, it is tissue architecture, immunohistochemistry and molecular analysis rather than cellular features that are essential for accurate pathological assessment [636,637]. For benign diseases, e. g. autoimmune pancreatitis [209,216], differential diagnosis of SET (GIST vs. leiomyoma or schwannoma) [94,280,288,290,295,298], subtyping of NSCLC and malignant lymphoma [310,332,361,424,538], diagnosis of rare tumors [221,340,521], grading of neuroendocrine tumors [203 -205], molecular profiling of solid tumors [180 -184, 186, 307 -309, 311 -313, 517, 643, 644] and differential diagnosis of mediastinal lymph node metastases [94,340,356], a core sample is preferred to a cytological aspirate [110]. Immunohistochemistry and molecular analysis will become increasingly important to allow personalized oncological treatment [180 -184, 186, 307 -309, 311 -313, 517, 643].…”

“…For most indications, cytopathological and histopathological assessment should be used in a complementary manner rather than exclusively. Cytopathological methods perform better for the evaluation of nuclear and cellular characteristics, while histopathological assessment of CB and core samples are advantageous over cytopathological assessment in cases in which immunohistochemistry is able to establish a diagnosis, e. g. in non-PDAC, gastrointestinal SETs, rare benign diseases, and lymphadenopathy [94,148,216,221,281,283,290,310,332,340,354,356,361,369,372,650].…”